UNS - Unilife Corporation

[LeeTV]

thanks Lee for posting and the video
I only have a small holding which I got for 1.23 it seemed to be going sideways
will now hold and wait

James

It's taking longer than most thought to take hold in the US but I think momentum is now with UNIS. Cracking open on the NASDAQ tonight on great volume. Expect UNS to run again tomorrow.


Unilife Corporation(NasdaqGM: UNIS)
Real-Time: 7.25 0.98 (15.63%) 9:52AM EDT

Last Trade: 7.41
Trade Time: 9:37AM EDT
Change: 1.14 (18.18%)
Prev Close: 6.27
Open: 7.18
Bid: 7.35 x 600
Ask: 7.40 x 100
1y Target Est: 15.00
Day's Range: 7.00 - 7.25
52wk Range: 5.41 - 26.40
Volume: 568,154
Avg Vol (3m): 195,332
Market Cap: 389.87M
P/E (ttm): N/A
EPS (ttm): -0.16
Div & Yield: N/A (N/A)

 

[LeeTV]

Unilife Enters Indian Healthcare Market

Begins Discussions with Local Healthcare and Pharmaceutical Leaders
LEWISBERRY, Pa., April 29 /PRNewswire-FirstCall/ -- Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS; ASX: UNS), a leading developer of safety medical devices, today announced its entry into the Indian market to help support efforts by the Central Government of India and international agencies to institute the mandatory use of safety syringes within local healthcare facilities.

Dr. Gerald Verollet, Vice-President of Scientific and International Affairs, has relocated to India to co-ordinate discussions between Unilife and government agencies, healthcare facilities and pharmaceutical companies regarding the use of Unilife's proprietary range of safety syringes. Prior to joining Unilife in 2003, Dr. Verollet was the head of Medical Devices at the World Health Organization (WHO), playing a key role in the development and adoption of international standards for Auto-Disable (AD) syringes that incorporate safety features to automatically prevent the reuse and sharing of syringes.

Unilife has also appointed Clinicare, a Mumbai-based national leader in the supply of innovative safety medical devices to Indian healthcare facilities and pharmaceutical companies, as its exclusive local partner. In addition to supporting Unilife's business development activities within India, Clinicare will also act as the Company's authorized national representative to secure the registration of its Unitract™ 1mL syringes with local regulatory authorities.

India is one of the largest and fastest growing markets for medical devices and pharmaceutical products, with many world-class healthcare facilities now established across the country. Last year, the Central Government of India enacted legislation requiring all affiliated hospitals within the country to use only AD syringes. The adoption of laws mandating the use of single use syringes reflects estimates by WHO that between one half to two-thirds of the four billion injections administered in India each year are unsafe. Up to one-third of these unsafe injections are estimated to carry the risk of transmitting blood-borne viruses such as HIV and hepatitis C.

Mr. Alan Shortall, CEO of Unilife, stated, "Unilife is an emerging global leader for innovative safety medical devices that is committed to enhancing and saving lives worldwide. While much of our focus remains on North America and European markets, our entry into India at this time represents a smart strategic move. India is one of the world's fastest growing healthcare markets, with a large number of excellent hospitals and established pharmaceutical companies."

Dr. Verollet stated, "The mandatory use of AD syringes within India is a positive move that will help to improve injection safety standards across the country. However healthcare workers still remain at significant risk of infection from needlestick injuries from the AD syringes currently available in India. These AD syringes are not able to protect healthcare workers from needlestick injuries alone, because the needle still remains exposed after use.

"With a recent report finding that up to 80% of healthcare workers in New Delhi hospitals had incurred a needlestick injury in the last year, it is clear that Indian healthcare workers remain at significant risk. As such, we believe Unilife has a significant opportunity to introduce its Unitract™ Syringe with its unique automatic and controlled needle retraction features into a market that can benefit greatly from a health and humanitarian standpoint. I believe Unilife's range of safety syringes, which go beyond a simple AD feature, can offer the most effective solution to global unsafe injection practices. By working with Indian government departments, pharmaceutical companies and healthcare facilities, we hope to begin to play a role in the provision of the highest possible injection safety standards to Indian healthcare workers," concluded Dr. Verollet.

The Unitract™ range of prefilled and clinical use syringes is the only known technology that combines the key feature of passive (automatic) and operator-controlled needle retraction with an independent AD feature. Operators are able to control the speed of automatic needle retraction directly from the body into the barrel of the syringe, where the needle is automatically locked, to virtually eliminate the risk of infection via potential transmission modes such as needlestick injuries, aerosol and reuse.

Mr Jagdeep Shah, Director of Clinicare, stated, "We see an excellent opportunity in India for introducing the Unitract™ range of 1mL safety syringes for use within local healthcare facilities. Indian healthcare workers remain at significant risk of exposure to bloodborne pathogens due to needlestick injuries. This is a grave national concern that needs better management. Given the high standards of many Indian healthcare facilities and the desire for local pharmaceutical companies to gain a competitive advantage, I believe Unilife is well positioned to build quality relationships with local government and industry leaders."

 

[nawshus]

Good news, UNI is making big moves. Thanks LeeTV for keeping us informed with you're quick announcements.

 

[chb]

(RTTNews) - Unilife Corp. (UNIS) announced preliminary financial results for the third quarter, posting a loss of $12.1 million or $0.23 per share, compared to a loss of $0.3 million or $0.01 per share in the same period last year. Adjusted net loss for the quarter was $5.1 million or $0.10 per share, compared to adjusted net income of $0.5 million or $0.01 per share in the year-ago period.

On average, six analysts polled by Thomson Reuters expected the company to report earnings of $0.23 per share. Analyst's estimate typically exclude special items.

Revenues for the period were $2.4 million, compared to $4.1 million in the previous year quarter.

Read more: http://www.nasdaq.com/aspx/company-...fe-q3-loss-widens---quick-facts#ixzz0nx58BgkF

 

[pacestick]

Alan Shortall recently held a briefing sessionas required by Nasdaq.The following information was given. All italic words are my comments
1. The one mil production line is now being run 24 hours a day and 7 days a week maintained by four 6 hour shifts . This means that this assembly line is producing 40 million syringes a year, .
2. The orders from stetson are for one million syringes a year with the possibility of increases in the supply as Stetson require .
3. Mr Shortall said that interest in the one ml exceeds the capability of the assembly line
4. Introduced to prospective USA distributor by Stasson which resulted in the Americans doing trials which were a great success
5. Because of 2, 3 and 4 I would expect Unilife to commence building another one ml assembly line soon

6. Unifil final stage well on track The Unifill assembly line is being built by Mikron in Denver Colorado and is due to be shipped to the Unilife factory in October when there will be four weeks of tests before the handover
$34M in cash still remaining
cash burn $1.6m per month
7. Cash flow in should start in the third quarter of 2010 but not become serious money until first quarter 2011 from the on there should be an increasing cash flow .

 

[pacestick]

CHANGES IN SYRINGE MARKET

Becton Dickenson the world’s largest manufacturer of syringes has sold some of its non syringe but profit making operations in order to fund further development of their syringe range. This follows their unsuccessful defence of patent breach for their retractable syringe. They have obtained a court injunction to allow them to continue production while they prepare an appeal. One of their options is to purchase a competitor or competitors. The obvious ones would be
1. ritract the manufacturer of vanishpoint syringe which has the technology that they were using
2. Unilife which would give them superior technology to vanishpoint and give them access to even a near monopoly of the growing prefill market.

http://www.bd.com/contentmanager/b_...de=20001&d=&s=press&dTitle=Press&dc=&dcTitle=

 

[pacestick]

UNS posted a good rise on Friday Price up 12.5% and volume about 3 times average
However this was nothing compared to the UNIS trading on the Nasdaq where there was 8.12% rise, on volume of 6 942 345 !! with 3,015,316. traded after close This compares to a daily average of about 30184 Stand by for a large buy of CDIs on the asx tomorrow morning

 

[JBR]

UNS posted a good rise on Friday Price up 12.5% and volume about 3 times average
However this was nothing compared to the UNIS trading on the Nasdaq where there was 8.12% rise, on volume of 6 942 345 !! with 3,015,316. traded after close This compares to a daily average of about 30184 Stand by for a large buy of CDIs on the asx tomorrow morning

Do you mean sell ? Dropped 5% today and at one point down 8%. Not what I expected thats for sure.
Will be interesting to see how UNIS goes on the NASDAQ tonight.

 

[pacestick]

sorry i didnt allow for it being sunday in the USA I am convinced that many shorted UNI in order to fill orders created by Funds when UNIS was added to the Russell 3000 index They will need to get the shares from somewhere and Buying CDIs and converting them would seem to be the way to go

 

[pacestick]

With both volume and price down overnight I give up on predicting where it will go It is still possible that they may have to buy CDIs in the next few days to covered short positions otherwise we are left with the incredible figures of over 50% of the shares on the nasdaq changing hands in one day

 

[pacestick]

Unilife has been admitted to the Russell 3000 index. This is a list of companies used by investment funds in the USA to determine where they will place their funds. The Russell indexes seek to list the best companies in the world they are not ranked one to three thousand but there is also a Russell 2000 index which Unilife is not on.

THE METHODOLOGY OF THE RUSELL INDEXES


Russell produces a family of market cap-weighted U.S. equity indexes. All U.S. indexes are subsets of the Russell 3000E™ Index, which represents approximately 99% of the U.S. equity market.

This is a summary of how these indexes are constructed. We also offer an in-depth description of the index methodology (PDF).

Purpose
• Act as a performance standard for active managers.
• Serve as a proxy for asset allocation purposes.
• Become a purchasable and replicable vehicle for passive investment strategy.

Determining index membership
• Rank the U.S. common stocks from largest to smallest market capitalization at each annual reconstitution period (May 31).
• Top 3,000 stocks become the Russell 3000 ® Index.
• Largest 1,000 stocks become the Russell 1000 ® Index.
• Next 2,000 stocks become the Russell 2000 ® Index.
• The smallest 1,000 in the Russell 2000 Index plus the next smallest 1,000 comprises the Russell Micro cap Index.

Determining style index membership
• Rank each stock in the Russell 1000 and Russell 2000 by two variables: the book-to-price ratio and the I/B/E/S forecast long-term growth mean.
• Combine variables to create a composite value score (CVS) for each stock.
• Rank the stocks by their CVS and apply a non-linear probability algorithm to the distribution to determine style membership weights. Roughly 70% are classified as all value or all growth and 30% are weighted proportionately to both value & growth.

Exclusions
• Stocks trading below $1.00.
• Pink sheet and bulletin board stocks.
• Closed-end mutual funds, limited partnerships, royalty trusts, etc.
• Foreign Stocks and American Depositary Receipts (ADRs).

Adjustments
• Adjust shares outstanding for cross ownership and privately held shares to reflect shares available for trading.
• Adjust book value due to FAS 106 & 109 write-offs when determining price-to-book ratio for style classification.

Maintenance
• Stocks deleted between reconstitution dates are not replaced.
• Spin-offs and Initial Public Offerings are the only additions between reconstitution dates.
• Dividends are reinvested on the ex-date.

http://www.russell.com/indexes/membership/methodology/russell_us_indexes_methodology.asp



MARKET MAKERS

You probably take for granted that you can buy or sell a stock at a moment's notice. Place an order with your broker, and within seconds, it is executed. Have you ever stopped to wonder how this is possible? Whenever an investment is bought or sold, there must be someone on the other end of the transaction.

If you wanted to buy 1,000 shares of Disney, you must find a willing seller, and visa versa. It's very unlikely you are always going to find someone who is interested in buying or selling the exact number of shares of the same company at the exact same time. This begs the question, how is it that you can buy or sell anytime? This is where a market maker comes in.
A market maker is a bank or brokerage company that stands ready every second of the trading day with a firm ask and bid price. This is good for you, because when you place an order to sell your thousand shares of Disney, the market maker will actually purchase the stock from you, even if he doesn't have a seller lined up. In doing so, they are literally "making a market" for the stock.
How do Market Makers make their Money?
Market Makers must be compensated for the risk they take; what if he buys your shares in IBM then IBM's stock price begins to fall before a willing buyer has purchased the shares? To prevent this, the market maker maintains a spread on each stock he covers. Using our previous example, the market maker may purchase your shares of IBM from you for $100 each (the ask price) and then offer to sell them to a buyer at $100.05 (bid). The difference between the ask and bid price is only $.05, but by trading millions of shares a day, he's managed to pocket a significant chunk of change to offset his risk.
http://beginnersinvest.about.com/od/beginnerscorner/l/blmarketmakers.htm

Unilife was admitted to the Russell 3000 on the 25 June as a result there was a significant increase in trades of Unilife on the NASDAQ that day Alan Shortall CEO of Unilife made the following comment on the 28 June
Most companies that joined the Russell 3000 and associated indexes, including Unilife Corporation, experienced a significant increase in the trading volume of their common stock on U.S. exchanges on Friday, June 25. There were almost seven million Unilife shares traded on Friday, which is the equivalent of 41.7 million CDIs with a value of approximately US$50 million. We expect much of the increase in Unilife trading volume on Friday represented the inflow of U.S. investors that track the Russell indexes." said Mr. Shortall.
As this would of represented a significant proportion of the shares available for the NASDAQ and as it is unlikely that such a high proportion of shareholders would of sold I for one expected that the difference between the shares sold on the NASDAQ and those available to be made up from the purchase of CDIs on the ASX n and transferring them To the NASDAQ however the amount of shares transferred from the ASX to the NASDAQ in the following days fell well short of the expected difference .
I would speculate therefore that the market Makers acted in a way similar to this
1. Held a small amount of shares
2. Churned the shares causing the 7 million trades The NASDAQ only records one million 1 hundred thousand as being accumulated in total on trades that day
3. Purchased a small amount of CDIS after the day to fill any gaps

This theory doesn’t quite make sense as their would still be a deficit but it’s the best I can come up with

 

[pacestick]

looks like the answer is that the difference is shorted . When they have to settle or if they have to it at all i don't know maybe they can keep rolling it over

http://www.nasdaq.com/aspxcontent/shortinterests.aspx?symbol=UNIS&selected=UNIS

 

[Mink178]

So what is happening with UNS I havent been following my shares lately due to no movement for ages. where is UNS heading in the next few months? I thought this share was meant to gain momentum near the end of 2010 with factories completed and sales beginning and contracts signed etc etc..

 

[UBIQUITOUS]

So what is happening with UNS I havent been following my shares lately due to no movement for ages. where is UNS heading in the next few months? I thought this share was meant to gain momentum near the end of 2010 with factories completed and sales beginning and contracts signed etc etc..

Lol. Have you been reading Hotcopper? The Unilife thread on there is full of bull. There are a couple of good posters, but the rest are just dribblers who are trying to ramp the stock.

Yes, the company has a very bright future. However, I would not go by any share price predictions on Hotcopper.

 

[pacestick]

So what is happening with UNS I havent been following my shares lately due to no movement for ages. where is UNS heading in the next few months? I thought this share was meant to gain momentum near the end of 2010 with factories completed and sales beginning and contracts signed etc etc..

the factory is still being built the contract re sanofi Aventis is still to be signed they cant produce untill the production line is built and installed in the as yet partially built factory so there is no point in signing re prefills before hand as far as other syringes are concerned i have always believed it will be a slow penetration of the market and could take two or three years to make significant progress.

Both the factory and the production line are due in October so I am of the opinion that we wont see any significant movement before October November

 

[Mink178]

Re: UNS - share price going down

hi everyone, would just like to ask if anyone has an idea why the share prices are going down for the past few days now... also any idea when it might start to climb up again?

 

[UBIQUITOUS]

Re: UNS - share price going down

hi everyone, would just like to ask if anyone has an idea why the share prices are going down for the past few days now... also any idea when it might start to climb up again?

I don't know why it is falling, but can tell you that the price will start to climb again on September 20 at 10:09 am

 

[Mink178]

Re: UNS - share price going down

but can tell you that the price will start to climb again on September 20 at 10:09 am

What is the significant event that will be happening on September 20 to make the price climb again??

 

[Draco5]

Re: UNS - share price going down

I don't know why it is falling, but can tell you that the price will start to climb again on September 20 at 10:09 am

On September 20 at 10:08 I'm going to buy up big.
Thanks for the tip UBIQUITOUS.

 

[ParleVouFrancois]

I think he's talking about the factory being officially opened, which is also when Sanofi Aventis sign their purchasing deal with Unilife.

Not sure though, DYOR for certainty.